SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment of ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

The MarketWatch News Department was not involved in the creation of this content. Addressing a Leading Cause of Hospitalization in Older Adults with Heart Failure BURLINGTON, Mass., Feb. 9, 2026 ...

Credit: scPharmaceuticals. Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration. Furoscix ® ...

How Lasix Injection works Lasix Injection is a diuretic. Lasix Injection may be unsafe to use during pregnancy. Lasix Injection is probably safe to use during breastfeeding. Lasix Injection may ...

Please provide your email address to receive an email when new articles are posted on . scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for ...

CHICAGO -- The choice between furosemide and torsemide didn't matter for longer-term clinical outcomes of hospitalized heart failure patients, according to the comparative effectiveness trial ...

Subcutaneous (SC) furosemide, a novel way to deliver diuretic therapy, may improve symptoms and functional capacity in patients with heart failure (HF) and worsening congestion, according to results ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...